Media Focus

Nov 30, 2021

Korea-based ST Pharm takes leap towards world's largest oligonucleotide CDMO

  • To build the second oligonucleotide manufacturing plant for an expansion of production facilities and to preoccupy the rapidly growing oligonucleotide therapeutics market.
  • Will invest in total $126 million at Banwol campus located in Ansan until 2025.